March 10, 2005 Investors celebrated the five-year anniversary of the Nasdaq top it hit a price of 5048 on this day in 2000 by refusing to get emotional. Although the Centient Biotech 200 traded both higher and lower, in the end it finished not far from its starting point. The CBT 200 was down almost 7 points at 3175.56, a .22% drop. Both the NYSE Composite and the Nasdaq were almost unchanged. We discuss the latest twists in the story of controversial Biovail, continuing collateral damage from the Tysabri recall, a supplier-caused shortfall for Martek, a follow-on offering from Vivus, which didn’t seem to please investors, and an avian flu vaccine from Sanofi-Aventis. More details provided...
